Closing
Do diet, exercise & lifestyle improve liver & MASLD versus placebo?
Mostly studied in obesity & overweight.
Mechanistic model availableWhy does fat build up in the liver in type 2 diabetes?See where the mechanism fails, how this treatment's effect is predicted and validated against held-out trials, and the decisive experiments that remain. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 0
Already under way
- Effect of AI-assisted Multi-domain Lifestyle Intervention Versus Tirzepatide Treatment on Weight Loss Maintenance in Adults With Type 2 Diabetes: a Randomized…NCT07555730 · not yet recruiting · started 2026
- Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational…NCT07589322 · recruiting · started 2026
- Semaglutide for Metabolic and Adiposity-Related Targets in Youth With Autism Spectrum Disorder (SMART-ASD)NCT07770152 · not yet recruiting · started 2026
- Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide…NCT06764056 · not yet recruiting · started 2025
- Effects of GLP-1 Receptor Agonists Combined with Metformin and Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Women with…NCT06775093 · not yet recruiting · started 2025
The evidence so far
- Registered trials
- 27
- With posted results
- 2
- Published papers
- 2
Of 2 decided analyses: 2 favor diet, exercise & lifestyle, 0 find no difference, 0 favor the comparator.
Papers
- A fasting-mimicking diet programme reduces liver fat and liver inflammation/fibrosis measured by magnetic resonance imaging in patients with type 2 diabetes.Trial report · 2025
- Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.Meta-analysis / systematic review · 2024
Trials
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)NCT02798744
- Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled TrialNCT02409238
- A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric RestrictionNCT02616003
- Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingNCT02963935 · 1 posted result
- A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 DiabetesNCT00263965
- A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian DysfunctionNCT07326111
- An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and AdolescentsNCT01487993
- An Intervention Study Investigating Effect of Dietary Protein Supplementation on Body Weight and Metabolic HomeostasisNCT06989203